Covers an expanded panel of biomarkers, including all NTRK fusions, HRR genes, and bTMB.1-3*
bTMB, blood-based tumor mutation burden; HRR, homologous recombination repair; NTRK, neurotrophic tyrosine receptor kinase.
*HRR genes include BRCA1/2, ATM, PALB2, FANCA, RAD51D, CHEK2, CDK12.¹⁻³
†Pathogenic germline and somatic variants.
Important note: Guardant360 was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.